Veru Inc
NASDAQ:VERU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Veru Inc
Intangible Assets
Veru Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Veru Inc
NASDAQ:VERU
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Estee Lauder Companies Inc
NYSE:EL
|
Intangible Assets
$3.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
28%
|
|
|
Bellring Brands Inc
NYSE:BRBR
|
Intangible Assets
$120.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Coty Inc
NYSE:COTY
|
Intangible Assets
$3.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inter Parfums Inc
NASDAQ:IPAR
|
Intangible Assets
$325.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
elf Beauty Inc
NYSE:ELF
|
Intangible Assets
$564.2m
|
CAGR 3-Years
92%
|
CAGR 5-Years
42%
|
CAGR 10-Years
17%
|
|
Veru Inc
Glance View
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 252 full-time employees. The firm is focused on developing medicines for the management of breast and prostate cancers. The firm's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. The company has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
